Adjunct Assistant Professor, Department of Languages and Cultures
BSc, University of Alexandria, Egypt
MS, University of Wisconsin
PhD, University of North Carolina
Dr. Elgebaly is the founder of Nour Heart, Inc, whose research resulted in the discovery of Nourin, Nourin antagonists, and Nourexal. Before founding Nour Heart in 1997, Dr. Elgebaly was Associate Professor at the University of Connecticut School of Medicine where she researched Nourin as a novel unique tissue-derived inflammatory mediator and Nourexal as a cardioprotective and neuroprotective agent. Dr. Elgebaly has extensive experience in both drug development and clinical trials. Dr. Elgebaly has been awarded over seven million dollars and more than 33 grants from organizations such as the National Institute of Health, pharmaceutical companies, academia, and corporate competitive awards. Additionally, she is the author of four issued patents, ten pending patents, more than 45 peer-reviewed scientific articles, and over 65 abstracts. She is a frequent lecturer on the subject of Nourin and Nourexal and was invited by two Nobel Prize Winners in Medicine, Professor Sir John Vane, London, UK, and Professor R. Levi Montalcini, Rome, Italy.
Dr. Elgebaly began teaching Arabic at USNA in 2007. Dr. Elgebaly's research is focused at understanding the role of "summarizing" Arabic grammar and concepts in advancing student learning and practicing of the Arabic language.